Nothing Special   »   [go: up one dir, main page]

DK1450847T3 - Apo2-ligand/TRAIL-formuleringer og anvendelser deraf - Google Patents

Apo2-ligand/TRAIL-formuleringer og anvendelser deraf

Info

Publication number
DK1450847T3
DK1450847T3 DK02784443.0T DK02784443T DK1450847T3 DK 1450847 T3 DK1450847 T3 DK 1450847T3 DK 02784443 T DK02784443 T DK 02784443T DK 1450847 T3 DK1450847 T3 DK 1450847T3
Authority
DK
Denmark
Prior art keywords
formulations
trail
applications
apo2 ligand
trail formulations
Prior art date
Application number
DK02784443.0T
Other languages
English (en)
Inventor
Heather Flores
Roger Pai
Zahra Shahrokh
Tanya P Lin
Timothy C Matthews
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK1450847T3 publication Critical patent/DK1450847T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DK02784443.0T 2001-11-13 2002-11-12 Apo2-ligand/TRAIL-formuleringer og anvendelser deraf DK1450847T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33824901P 2001-11-13 2001-11-13
PCT/US2002/036251 WO2003042344A2 (en) 2001-11-13 2002-11-12 Apo2 ligand/trail formulations

Publications (1)

Publication Number Publication Date
DK1450847T3 true DK1450847T3 (da) 2010-12-13

Family

ID=23324037

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02784443.0T DK1450847T3 (da) 2001-11-13 2002-11-12 Apo2-ligand/TRAIL-formuleringer og anvendelser deraf

Country Status (11)

Country Link
US (3) US7741282B2 (da)
EP (3) EP1450847B1 (da)
JP (2) JP2005521640A (da)
AT (1) ATE482716T1 (da)
CA (1) CA2466054C (da)
DE (1) DE60237841D1 (da)
DK (1) DK1450847T3 (da)
ES (1) ES2351786T3 (da)
IL (3) IL161812A0 (da)
PT (1) PT1450847E (da)
WO (1) WO2003042344A2 (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2311956A1 (en) * 1999-06-28 2011-04-20 Genentech, Inc. Methods for making APO-2 ligand using divalent metal ions
US7741285B2 (en) * 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations
WO2004060920A1 (en) * 2002-12-31 2004-07-22 Altus Pharmaceuticals Inc. Complexes of protein crystals and ionic polymers
DK1581251T3 (da) 2002-12-31 2016-06-27 Althea Tech Inc Krystaller af humant væksthormon og fremgangsmåder til fremstilling deraf
US20060019234A1 (en) * 2004-07-22 2006-01-26 Shanbrom Technologies, Llc Modern blood banking employing improved cell preservation composition
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
US20090155247A1 (en) * 2005-02-18 2009-06-18 Ashkenazi Avi J Methods of Using Death Receptor Agonists and EGFR Inhibitors
US20060188498A1 (en) * 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
EP1890723A2 (en) * 2005-06-06 2008-02-27 Novo Nordisk A/S Stabilised il-21 compositions
EP2306200A1 (en) * 2005-08-16 2011-04-06 Genentech, Inc. Apoptosis sensitivity to Apo2L/TRAILl by testing for GalNac-T14 expression in cells/tissues
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
PL1962886T6 (pl) * 2005-12-20 2023-03-13 Bristol-Myers Squibb Company Stabilne formulacje białkowe
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
EA023303B1 (ru) 2007-08-15 2016-05-31 Сиркейшиа Лимитед Пептидная композиция для формирования толерантности к клещам домашней пыли и ее применение
EP2205282A2 (en) 2007-09-24 2010-07-14 Bar-Ilan University Polymer nanoparticles coated by magnetic metal oxide and uses thereof
EP2111871A1 (de) * 2008-04-26 2009-10-28 Sandoz AG Stabilisierte Flüssigformulierung
US8980610B2 (en) 2008-11-20 2015-03-17 Biogen Idec Ma Inc. Arginine inactivation of viruses
GB0821806D0 (en) 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
DE102008064553B4 (de) * 2008-12-22 2015-05-13 Technische Universität Dresden Verfahren zum Nachweis und/oder zur Identifizierung hormonell wirksamer Substanzen
US8293100B2 (en) 2009-03-13 2012-10-23 Terrasep, Llc Methods and apparatus for centrifugal liquid chromatography
JP5984676B2 (ja) 2009-12-18 2016-09-06 シーエスエル、リミテッド ポリペプチドを精製する方法
KR101880905B1 (ko) 2010-04-27 2018-07-23 에스씨아이엘 테크놀로지 게엠베하 안정한 수성 ｍｉａ／ｃｄ－ｒａｐ 제제
RU2012151500A (ru) * 2010-05-03 2014-06-10 Дженентек, Инк. Композиции и способы, пригодные для снижения вязкости белковосодержащих составов
EP2704735A1 (en) 2011-05-03 2014-03-12 Genentech, Inc. Vascular disruption agents and uses thereof
RU2014150071A (ru) * 2012-05-11 2016-07-10 Новартис Аг Способы кристаллизации для очистки моноклональных антител
WO2014199373A1 (en) * 2013-06-09 2014-12-18 Efranat Ltd. Compositions comprising gc- macrophage activating factor and uses thereof
US11279768B1 (en) 2015-04-03 2022-03-22 Precision Biologics, Inc. Anti-cancer antibodies, combination therapies, and uses thereof
US10501744B2 (en) 2016-05-04 2019-12-10 Indiana University Research And Technology Corporation Presentation of bioactive proteins
EA202191385A1 (ru) * 2018-12-21 2021-11-15 Икнос Сайенсис С.А. Способы осветления культур клеток

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
JPS5829958B2 (ja) * 1977-03-07 1983-06-25 工業技術院長 タンパク質結晶の形成方法
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
JPS60126084A (ja) * 1983-12-13 1985-07-05 Toyo Jozo Co Ltd グリセロリン酸オキシダーゼの安定化法
JPS62283932A (ja) 1986-05-29 1987-12-09 Green Cross Corp:The 組織プラスミノ−ゲンアクチベ−タの乾燥製剤
ATE76311T1 (de) 1986-08-19 1992-06-15 Genentech Inc Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und zytokinen.
JP2602850B2 (ja) * 1987-10-27 1997-04-23 富士通株式会社 単結晶作製方法
EP0397687B1 (en) 1987-12-21 1994-05-11 The University Of Toledo Agrobacterium mediated transformation of germinating plant seeds
DK168302B1 (da) 1989-06-29 1994-03-07 Danisco Fremgangsmåde til indføring af molekyler, især genetisk materiale i planteceller
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
CH682806A5 (de) 1992-02-21 1993-11-30 Medimpex Ets Injektionsgerät.
JP3007785B2 (ja) * 1993-03-16 2000-02-07 旭化成工業株式会社 トロンボモジュリン組成物およびその変性防止方法
ATE503013T1 (de) 1995-06-29 2011-04-15 Immunex Corp Cytokin welches apoptose induziert
US6284236B1 (en) 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
US6030945A (en) 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
TWI240627B (en) * 1996-04-26 2005-10-01 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
ES2248823T5 (es) 1996-10-25 2011-11-03 Human Genome Sciences, Inc. Neutroquina alfa.
PT951551E (pt) 1996-12-23 2008-10-28 Immunex Corp Ligando para receptor activador de nf-kb, ligando membro da superfamília de tnf
JP4450870B2 (ja) 1997-01-28 2010-04-14 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 死ドメイン含有レセプター４（ｄｒ４：死レセプター４）、ｔｎｆ−レセプタースーパーファミリーのメンバーおよびｔｒａｉｌへの結合
US6072047A (en) 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US20010010924A1 (en) 1997-03-14 2001-08-02 Keith Charles Deen Tumor necrosis factor related receptor, tr6 polynecleotides
DK0970213T3 (da) 1997-03-17 2007-05-21 Human Genome Sciences Inc Dödsdomæneholdig receptor
US6140475A (en) * 1997-04-11 2000-10-31 Altus Biologics Inc. Controlled dissolution crosslinked protein crystals
AU7126498A (en) 1997-04-16 1998-11-11 Millennium Pharmaceuticals, Inc. Tumor necrosis factor receptor related proteins tango-63d and tango-63e
RO128635A2 (ro) 1997-04-16 2013-07-30 Amgen Inc. Anticorp sau fragment al acestuia care se leagă la opgbp şi utilizarea acestuia, utilizarea unei forme solubile de odar, şi metodă de identificare a unui compus care descreşte activitatea opgbp
ES2293682T5 (es) 1997-05-15 2011-11-17 Genentech, Inc. Anticuerpo anti-apo2.
EP1032661A1 (en) 1997-06-18 2000-09-06 Genentech, Inc. Apo-2DcR
US6352730B1 (en) 1997-07-02 2002-03-05 The Procter & Gamble Co. Suspension for adding a controlled amount of ingredient to a food product
WO1999002653A1 (en) 1997-07-11 1999-01-21 Trustees Of The University Of Pennsylvania Nucleic acid encoding a novel chemotherapy-induced protein, and methods of use
WO1999006673A1 (en) 1997-07-30 1999-02-11 Eg & G Sealol, Inc. Improved brush seal and method of making same
JP2001514888A (ja) 1997-08-15 2001-09-18 アイドゥン ファーマシューティカルズ， インコーポレイテッド Ｔｒａｉｌレセプター、これをコードする核酸、およびその使用方法
CA2301847A1 (en) 1997-08-26 1999-03-04 Genentech, Inc. Rtd receptor
WO1999011791A2 (en) 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
WO1999036535A1 (en) 1998-01-15 1999-07-22 Genentech, Inc. Apo-2 ligand
JP4194681B2 (ja) * 1998-01-20 2008-12-10 太陽化学株式会社 可溶性γ−リベチン複合体の製造法
AU765003B2 (en) 1998-03-27 2003-09-04 Genentech Inc. Apo-2 ligand-anti-her-2 antibody synergism
GB2349636A (en) 1998-09-17 2000-11-08 Adv Liquid Packaging Corp Resealable can
FR2783596B1 (fr) 1998-09-23 2001-03-09 Eurokera Ensemble prefabrique destine a la realisation de tables de cuisson
WO2000075191A2 (en) 1999-06-09 2000-12-14 Genentech, Inc. Apo-2L RECEPTOR AGONIST AND CPT-11 SYNERGISM
EP2311956A1 (en) 1999-06-28 2011-04-20 Genentech, Inc. Methods for making APO-2 ligand using divalent metal ions
AUPQ312699A0 (en) 1999-09-28 1999-10-21 Electrical Moulded Components Pacific Pty Ltd Electrical reticulation apparatus
AU766984B2 (en) 1999-09-30 2003-10-30 Trustees Of The University Of Pennsylvania, The Trail: an inhibitor of autoimmune inflammation and cell cycle progression
ATE464062T1 (de) 1999-10-04 2010-04-15 Novartis Vaccines & Diagnostic Stabilisierte flüssige pharmazeutische zusammensetzung enthaltend tfpi
ES2220673T3 (es) * 2000-02-29 2004-12-16 Pfizer Products Inc. Factor estimulante de colonias de granulocitos estabilizado.
AU2001279055A1 (en) 2000-07-27 2002-02-13 Genentech, Inc. Apo-2L receptor agonist and CPT-11 synergism
WO2003029420A2 (en) * 2001-10-02 2003-04-10 Genentech, Inc. Apo-2 ligand variants and uses thereof
US7741285B2 (en) * 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations

Also Published As

Publication number Publication date
US8470969B2 (en) 2013-06-25
CA2466054A1 (en) 2003-05-22
JP2009108040A (ja) 2009-05-21
IL161812A0 (en) 2005-11-20
WO2003042344A3 (en) 2003-11-27
EP2322165A1 (en) 2011-05-18
EP2332531A1 (en) 2011-06-15
CA2466054C (en) 2012-01-03
EP1450847B1 (en) 2010-09-29
JP2005521640A (ja) 2005-07-21
IL161812A (en) 2013-02-28
JP5042959B2 (ja) 2012-10-03
WO2003042344A2 (en) 2003-05-22
EP1450847A2 (en) 2004-09-01
PT1450847E (pt) 2011-01-05
DE60237841D1 (de) 2010-11-11
EP2332531B1 (en) 2019-07-10
US7741282B2 (en) 2010-06-22
US20050020498A1 (en) 2005-01-27
ATE482716T1 (de) 2010-10-15
ES2351786T3 (es) 2011-02-10
US20110269947A1 (en) 2011-11-03
EP1450847A4 (en) 2007-08-29
IL197705A0 (en) 2009-12-24
US20050080006A1 (en) 2005-04-14

Similar Documents

Publication Publication Date Title
DK1450847T3 (da) Apo2-ligand/TRAIL-formuleringer og anvendelser deraf
EP1649006A4 (en) EXO-SPECIFIC AMYLASE POLYPEPTIDES, THESE POLYPEPTIDE-CODING NUCLEIC ACIDS, AND USES THEREOF
HK1131744A1 (en) Toll like receptor 3 antagonists, methods and uses toll
DE60325892D1 (de) Stellungs- und verwendungsverfahren
DK1343782T3 (da) Pyrimidinaminer som angiogenesemodulatorer
TR200202194T2 (tr) Poliglütamik asit-kamptotesin birleşikleri ve hazırlama yöntemleri
WO2003016282A3 (en) Substituted 1h-dihydropyrazoles, their preparation and use
WO2007051164A3 (en) Toll like receptor 3 modulators, methods and uses
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
TW200611910A (en) Interferon-alpha polypeptides and conjugates
ATE397084T1 (de) Lentivirale verpackungskonstrukte
DK1131444T3 (da) Polypeptider med lysophospholipase aktivitet og nucleinsyre som koder for disse
DK1083903T3 (da) Brobundne indenopyrrolocarbazoler
WO2004046365A3 (en) Interferon-alpha polypeptides and conjugates
WO2004087874A3 (en) Novel nucleic acids and polypeptides
DE60204701D1 (de) Tricyclische imidazopyridine
DK1680430T3 (da) Fremgangsmåder til fremstilling af form I af (S)-(+)-Clopidogrel-bisulfat
DK1465927T3 (da) BAG3-antistoffer til anvendelse til forskning, diagnostik og behandling af sygdomme, der omfatter celledød
DK2335720T3 (da) Autolog T-cellevacciner mod multiple sclerose
NO20012461L (no) Krystallmodifikasjon B av 8-cyano-1-cyklopropyl-7-(1S,6S-2,8- diazabicyklo(4.3.0)nonan-8-yl)-6-fluor-1,4-dihydro-4-okso-3-quinolinkarboksylsyre
DE60106686D1 (de) Thermisch stabilisierte PVC-Zusammensetzungen
EP1436279A4 (en) CHEMICAL COMPOUNDS
WO2005057486A3 (en) Protein engineering with analogous contact environments
SE0101700D0 (sv) Nucleotide sequences
WO2000068240A8 (en) NOVEL aroA